| Schedule of Information for the Company's Operating Segments |
Information for the Company's reportable segments for the three months ended September 30, 2016 and 2015 are as follows: | | | | | | | | | | | | Three months Ended September 30, 2016 | Consumer Operations | Drug Development | Corporate | Consolidated | Total revenue | $ | 599,074 |
| — |
| — |
| $ | 599,074 |
| Interest income, net | $ | — |
| — |
| 97,726 |
| $ | 97,726 |
| Loss from operations | $ | 2,690,601 |
| 5,550,853 |
| 2,493,766 |
| $ | 10,735,220 |
|
| | | | | | | | | | | | Three months Ended September 30, 2015 | Consumer Operations | Drug Development | Corporate | Consolidated | Total revenue | $ | — |
| — |
| — |
| $ | — |
| Interest income, net | $ | — |
| — |
| 14,637 |
| $ | 14,637 |
| Loss from operations | $ | 2,578,891 |
| 3,258,877 |
| 2,329,713 |
| $ | 8,167,481 |
|
Information for the Company's reportable segments for the nine months ended September 30, 2016 and 2015 are as follows: | | | | | | | | | | | | Nine months Ended September 30, 2016 | Consumer Operations | Drug Development | Corporate | Consolidated | Total revenue | $ | 711,759 |
| — |
| — |
| $ | 711,759 |
| Interest income, net | $ | — |
| — |
| 308,877 |
| $ | 308,877 |
| Loss from operations | $ | 8,461,803 |
| 15,517,670 |
| 7,922,492 |
| $ | 31,901,965 |
|
| | | | | | | | | | | | Nine months Ended September 30, 2015 | Consumer Operations | Drug Development | Corporate | Consolidated | Total revenue | $ | — |
| — |
| — |
| $ | — |
| Interest income, net | $ | — |
| — |
| 34,397 |
| $ | 34,397 |
| Loss from operations | $ | 5,412,144 |
| 9,177,410 |
| 6,693,666 |
| $ | 21,283,220 |
|
|